💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Talaporfin

CHEMBL2111186 Phase 4 승인됨 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
711.8 g/mol
LogP
3.5
Phase
4

Mono-L-aspartyl chlorin e6, known as talaporfin, is a second-generation chlorin photosensitiser used in photodynamic therapy. Illumination at 664 nm activates the accumulated compound, which generates singlet oxygen and other reactive oxygen species; these induce apoptosis and shut down the vasculature within the illuminated field, confining destruction to tissue that has been both sensitised and lit. Established applications are early-stage central lung cancer and early-stage oesophageal cancer, with investigation extending to age-related macular degeneration and benign prostatic hyperplasia. The chlorin structure absorbs near-infrared light more strongly than porphyrin photosensitisers and permits a shorter drug-to-light interval. The formula is C38H41N5O9, near 711.8 g/mol.

Talaporfin (mono-l-aspartyl chlorin e6) is a second-generation chlorin-based photosensitizer used in photodynamic therapy (PDT) for early-stage central lung cancer, early-stage esophageal cancer, and investigation in AMD and BPH. Upon activation by 664 nm red light, it generates cytotoxic singlet oxygen and reactive oxygen species that induce apoptosis and vascular shutdown in the illuminated target tissue. Its chlorin-based structure provides stronger near-infrared light absorption and shorter drug-to-light intervals than porphyrin-based photosensitizers.

분자량

711.8000 g/mol

LogP

3.50

TPSA

236.00 Ų

리핀스키 5의 법칙

불통과

치료 영역

Non-Small Cell Lung Cancer Oncology

작용 기전

Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C=Cc1c(C)c2cc3nc(c(CC(=O)N[C@@H](CC(=O)O)C(=O)O)c4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CC)c(C)c4C(=O)O)[C@@H](CCC(=O)O)[C@@H]3C

                

                

                
                

                    
InChI

                    
InChI=1S/C38H41N5O9/c1-7-20-16(3)24-12-26-18(5)22(9-10-32(45)46)35(42-26)23(11-31(44)41-30(37(49)50)15-33(47)48)36-34(38(51)52)19(6)27(43-36)14-29-21(8-2)17(4)25(40-29)13-28(20)39-24/h7,12-14,18,22,30,39,43H,1,8-11,15H2,2-6H3,(H,41,44)(H,45,46)(H,47,48)(H,49,50)(H,51,52)/b24-12-,25-13-,26-12-,27-14-,28-13-,29-14-,35-23-,36-23-/t18-,22-,30-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C38H41N5O9

                    

                    
                    

                        
HBD / HBA

                        
7 / 11

                    

                    
                    

                        
회전 가능 결합

                        
12

                    

                    
                    
                    

                        
무거운 원자

                        
52

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
Talaporfin (mono-l-aspartyl chlorin e6) is a second-generation chlorin-based photosensitizer used in photodynamic therapy (PDT) for early-stage central lung cancer, early-stage esophageal cancer, and investigation in AMD and BPH. Upon activation by 664 nm red light, it generates cytotoxic singlet oxygen and reactive oxygen species that induce apoptosis and vascular shutdown in the illuminated target tissue. Its chlorin-based structure provides stronger near-infrared light absorption and shorter drug-to-light intervals than porphyrin-based photosensitizers.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Talaporfin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2111186.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5486799.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.